Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous …
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous …
Major findings and recent advances in virus–like particle (VLP)-based vaccines
MO Mohsen, L Zha, G Cabral-Miranda… - Seminars in …, 2017 - Elsevier
Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last
three decades. VLPs constitute versatile tools in vaccine development due to their …
three decades. VLPs constitute versatile tools in vaccine development due to their …
Hepatitis B virus infection
C Trépo, HLY Chan, A Lok - The Lancet, 2014 - thelancet.com
Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the
world's population show serological evidence of current or past infection. Hepatitis B virus is …
world's population show serological evidence of current or past infection. Hepatitis B virus is …
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients
B Testoni, F Lebossé, C Scholtes, F Berby… - Journal of …, 2019 - Elsevier
Background & Aims It has been proposed that serum hepatitis B core-related antigen
(HBcrAg) reflects intrahepatic covalently closed circular (ccc) DNA levels. However, the …
(HBcrAg) reflects intrahepatic covalently closed circular (ccc) DNA levels. However, the …
The role of quantitative hepatitis B surface antigen revisited
In the past 10 years, there has been a lot of enthusiasm surrounding the use of serum
hepatitis B surface antigen (HBsAg) quantification to predict disease activity and monitor …
hepatitis B surface antigen (HBsAg) quantification to predict disease activity and monitor …
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
YF Liaw, JH Kao, T Piratvisuth, HLY Chan… - Hepatology …, 2012 - Springer
Large volume of new data on the natural history and treatment of chronic hepatitis B virus
(HBV) infection have become available since 2008. These include further studies in …
(HBV) infection have become available since 2008. These include further studies in …
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
Objective Little is known about the long-term clinical outcome and durability of HBsAg
seroclearance following nucleos (t) ide analogue (NUC) therapy in patients with chronic …
seroclearance following nucleos (t) ide analogue (NUC) therapy in patients with chronic …
[HTML][HTML] KASL clinical practice guidelines: management of hepatitis C
Korean Association for the Study of the … - Clinical and …, 2016 - ncbi.nlm.nih.gov
Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …
Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA
Abstract Background & Aims Hepatitis B virus (HBV) covalently closed circular DNA (ccc
DNA) is a key to viral persistence in chronic hepatitis B infection. Serum hepatitis B core …
DNA) is a key to viral persistence in chronic hepatitis B infection. Serum hepatitis B core …
New insight in the pathobiology of hepatitis B virus infection
M Dandri, S Locarnini - Gut, 2012 - gut.bmj.com
Chronic hepatitis B virus (HBV) infection remains a major health burden and the main risk
factor for the development of hepatocellular carcinoma worldwide. However, HBV is not …
factor for the development of hepatocellular carcinoma worldwide. However, HBV is not …